DDInter580 DDInter1676
Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Dofetilide {u} (Compound) resembles {v} (Compound) Dronedarone
Dofetilide {u} (Compound) resembles {v} (Compound) Rosiglitazone
Dofetilide {u} (Compound) binds {v} (Gene) KCNH2
Dofetilide {u} (Compound) upregulates {v} (Gene) CASP7
Dofetilide {u} (Compound) downregulates {v} (Gene) CDCA4
Dofetilide {u} (Compound) causes {v} (Side Effect) Dyspnoea
Dofetilide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Dofetilide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Troglitazone
Dofetilide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Dofetilide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Octreotide
Dofetilide (Compound) resembles Dronedarone (Compound)
Dofetilide (Compound) resembles Rosiglitazone (Compound)
Dofetilide (Compound) binds KCNH2 (Gene)
Dofetilide (Compound) upregulates CASP7 (Gene)
Dofetilide (Compound) downregulates CDCA4 (Gene)
Dofetilide (Compound) causes Dyspnoea (Side Effect)
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Troglitazone
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Octreotide